

University of Groningen

Translational Modeling in Schizophrenia

Johnson, Martin; Kozielska, Magdalena; Pilla Reddy, Venkatesh; Vermeulen, An; Barton, Hugh A; Grimwood, Sarah; de Greef, Rik; Groothuis, Geny M M; Danhof, Meindert; Proost, Johannes H

Published in:
Pharmaceutical Research

DOI:
[10.1007/s11095-015-1846-4](https://doi.org/10.1007/s11095-015-1846-4)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Johnson, M., Kozielska, M., Pilla Reddy, V., Vermeulen, A., Barton, H. A., Grimwood, S., ... Proost, J. H. (2015). Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy. *Pharmaceutical Research*. <https://doi.org/10.1007/s11095-015-1846-4>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy

Martin Johnson^{1,6} · Magdalena Kozielska^{1,7} · Venkatesh Pilla Reddy^{1,6} · An Vermeulen² · Hugh A. Barton³ · Sarah Grimwood³ · Rik de Greef⁴ · Geny M. M. Groothuis¹ · Meindert Danhof⁵ · Johannes H. Proost¹

Received: 8 October 2015 / Accepted: 10 December 2015 / Published online: 30 December 2015
© The Author(s) 2016. This article is published with open access at SpringerLink.com

ABSTRACT

Objectives To assess the ability of a previously developed hybrid physiology-based pharmacokinetic-pharmacodynamic (PBPKPD) model in rats to predict the dopamine D₂ receptor occupancy (D₂RO) in human striatum following administration of antipsychotic drugs.

Methods A hybrid PBPKPD model, previously developed using information on plasma concentrations, brain exposure and D₂RO in rats, was used as the basis for the prediction of D₂RO in human. The rat pharmacokinetic and brain physiology parameters were substituted with human population pharmacokinetic parameters and human physiological information. To predict the passive transport across the human blood–brain barrier, apparent permeability values were scaled based on rat and human brain endothelial surface area. Active efflux clearance in brain was scaled from rat to human using both human brain endothelial surface area and MDR1 expression. Binding constants at the D₂ receptor were scaled

based on the differences between *in vitro* and *in vivo* systems of the same species. The predictive power of this physiology-based approach was determined by comparing the D₂RO predictions with the observed human D₂RO of six antipsychotics at clinically relevant doses.

Results Predicted human D₂RO was in good agreement with clinically observed D₂RO for five antipsychotics. Models using *in vitro* information predicted human D₂RO well for most of the compounds evaluated in this analysis. However, human D₂RO was under-predicted for haloperidol.

Conclusions The rat hybrid PBPKPD model structure, integrated with *in vitro* information and human pharmacokinetic and physiological information, constitutes a scientific basis to predict the time course of D₂RO in man.

KEY WORDS antipsychotic · dopamine D₂ receptor occupancy · PBPK · schizophrenia · translational research

✉ Johannes H. Proost
j.h.proost@rug.nl

¹ Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

² Clinical Pharmacology & Pharmacometrics, Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium

³ Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut, USA

⁴ Quantitative Solutions, Pivot Park, Molenweg 79, 5349 AC Oss, The Netherlands

⁵ Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden, The Netherlands

⁶ Present address: AstraZeneca, Cambridge, UK

⁷ Present address: Institute of Engineering, Hanze University of Applied Sciences, Assen, The Netherlands

ABBREVIATIONS

BBB	Blood–brain barrier
CL	Clearance
CL _{bev}	Brain extra-vascular clearance (passive permeability clearance across the BBB)
CL _{eff}	Active efflux clearance across the BBB
CLZ	Clozapine
ER	Efflux ratio
h	Human (prefix)
HAL	Haloperidol
HBSA	Human brain endothelial surface area
K _d	<i>In vivo</i> receptor equilibrium dissociation constant
K _i	<i>In vitro</i> receptor equilibrium dissociation constant determined in inhibition study
k _{off}	Receptor dissociation rate constant
k _{on}	Receptor association rate constant

MDRI-MDCK	Multidrug resistance Madin-Darby canine kidney
OLZ	Olanzapine
PAL	Paliperidone
Papp	Apparent permeability across the BBB
PBPKPD	Physiology-based pharmacokinetic-pharmacodynamic model
PE	Prediction error
PET	Positron emission tomography
Pgp	P-glycoprotein
PK	Pharmacokinetic
PKPD	Pharmacokinetic-pharmacodynamic
PS	Product of membrane permeability and surface area
QTP	Quetiapine
r	Rat (prefix)
RIS	Risperidone
RO	Receptor occupancy
SPECT	Single-photon emission computed tomography

INTRODUCTION

In schizophrenia drug therapy and research, dopamine D₂ receptor occupancy (D₂RO) is often used as a target biomarker to quantify the relationship between efficacy and side effects (1). Several studies suggest that blockade of 65 to 80% of D₂ receptors is the key to antipsychotic efficacy for both conventional neuroleptics and novel antipsychotics (2–4). D₂RO higher than 80% increases the risk of adverse effects such as extra pyramidal symptoms (5). Thus, D₂RO has a central role in antipsychotic drug discovery, drug development and therapy. Target occupancy is important both in early drug discovery, where accurate knowledge of the degree of occupancy could help to determine the suitability of a drug candidate for further development, and later in the drug development process, when target site occupancy measurements can guide dose selection (6). D₂RO is clinically measured using positron emission tomography (PET) or single-photon emission computed tomography (SPECT) methodology, which are both expensive and time-consuming. Tools to predict clinical D₂RO in preclinical drug discovery phases are therefore valuable. It is well known that current antipsychotics also activate or antagonize other targets in the central nervous system. For example, risperidone has a higher affinity for serotonin (5-HT_{2A}) receptors than for D₂ receptors (5). Extensions of this tool to other receptors would therefore increase the value of the current translation framework.

Recently, we have reported physiology-based pharmacokinetic-pharmacodynamic (PBPKPD) models to characterize the time course of D₂RO and 5-HT_{2A} receptor occupancy (5-HT_{2A}RO) in rats (7,8). The mechanistic and physiological

basis of these models should potentially allow the prediction of human PKPD properties using physiological parameters and prior information from *in vitro* and *in vivo* preclinical studies (9). The present investigation aimed to determine how these models can be used for translating receptor occupancy from rat to humans.

Development of a translation tool to predict human D₂RO (based on PKPD models) involves scaling information from rat to human. This involves accounting for drug distribution to the brain and the drug's ability to bind to striatal D₂ receptors. Drug distribution to the brain is not only characterized by passive diffusion but also by active efflux transporters present at the luminal surface of the blood–brain barrier (BBB). Similarities in the *in vitro permeability* values determined by various types of experiments provide a basis to integrate and scale information on passive drug transport to the brain from *in vitro* to *in vivo* or from one species to the other (10). However, differential expression and limited homology of drug transporters involved in active drug transport across the BBB leads to challenges when scaling active transport related information from one species to another (11). Notwithstanding divergent reports on the species independence of drug-specific parameters, integration of *in vitro* parameters with physiologically based PKPD modeling would increase the potential of successfully translating effects from preclinical species to humans (12).

Hence, the objective of this work was to explore different approaches to predict human striatal D₂RO using a generic translational PBPKPD model structure, which allows integration and scaling of information from preclinical *in vitro* or *in vivo* data to the human situation. Different approaches were compared to determine the minimal amount of information required for this translational work. A previously developed extended model structure (8) was also used to predict human 5-HT_{2A}RO based on these approaches.

METHODS

Data

This work was performed within the framework of the Dutch Top Institute Pharma project: Mechanism-based PK–PD modeling (<http://www.tipharma.com>). This mechanism-based PKPD modeling platform involves leading pharmaceutical companies worldwide, and academic institutes from the Netherlands. Three pharmaceutical companies who are the members of this mechanism-based PK–PD modeling platform, namely, Janssen Research and Development - Belgium, Merck Sharp and Dohme - The Netherlands and Pfizer Worldwide Research and Development – USA, provided human plasma concentration data for haloperidol (HAL), risperidone (RIS) and paliperidone (PAL, in extended release


Fig. 1 A schematic representation of the PBPKPD model. The model incorporates different processes to explain the time course of D_2RO . The brain pharmacokinetics describes the processes involved in the transport of drug from plasma to brain, and the striatum compartment explains the drug binding to receptors through the binding constants.

formulation) and helped with collection of human D_2 and 5-HT_{2A} receptor occupancy data. Clozapine (CLZ), HAL, olanzapine (OLZ), RIS, extended release formulation of PAL and quetiapine (QTP) were used in this study as model antipsychotic drugs. The observed human D_2RO for these antipsychotics were taken from the literature (2,13–24). For risperidone (RIS), human D_2RO was provided from the pharmaceutical companies who are involved in this project.

Population pharmacokinetic (PK) parameters for CLZ, OLZ, QTP and RIS were obtained from literature (1,25,26). However, no population PK models have been reported in literature for HAL and PAL. So, for these compounds in-house population PK models were developed. The population PK model for haloperidol was developed on the basis of data from 7 studies, comprised of 122 individuals [healthy volunteers ($n=20$) and schizophrenic patients ($n=102$)] and 515 plasma concentrations obtained across a wide dose range of 1 to 60 mg/day administered either as single or multiple doses. The population PK model for paliperidone-extended release was developed on the basis of data from 3 studies, comprised of 870 individuals and 4169 plasma concentrations obtained across a wide dose range of 3 to 15 mg/day administered as an OROS® once daily formulation.

Physiology-Based PKPD Model Structure

A PBPKPD model was previously developed and evaluated for its usefulness in describing the time course of brain concentration and D_2RO in rats (7). This model contains expressions to describe the kinetics in brain-vascular, brain-extravascular, striatum-free and striatum-bound compartments (Fig. 1). Following administration, drug is transported from the plasma compartment to the brain-vascular compartment; this process is assumed to be determined only by the cerebral blood flow. Only the unbound drug in this vascular compartment crosses the BBB and is transported into the brain-extravascular compartment, which is governed by the brain-extravascular clearance (CL_{bev}). Furthermore, drug is transported from the brain-extravascular compartment to the striatal-free compartment. The brain-extravascular and striatum-free compartments were assumed to be equilibrating rapidly. In striatum-bound compartment, drug can reversibly bind to the dopamine receptor complex (Fig. 1). The receptor association and dissociation processes were described using k_{on} as the receptor association rate constant ($nM^{-1}h^{-1}$), k_{off}



as the receptor dissociation rate constant (h^{-1}) and D_2 receptor density in striatum (nM).

In addition to the previously developed rat PBPKPD model structure, an active efflux clearance (CL_{eff}) component between brain-extravascular and brain-vascular compartments was included in this predictive model to reflect the active drug transport from brain, when appropriate (i.e., for RIS and PAL). Additionally, this rat PBPKPD model structure was extended to account for binding of RIS and PAL to the 5-HT_{2A} receptor (8). This extended model included two additional compartments (cortex-free and cortex-bound). Binding to 5-HT_{2A} receptors was described using association and dissociation constants and receptor density values specific for 5-HT_{2A} receptors. This extended model structure was used to predict both D_2 and 5-HT_{2A} receptor occupancy in humans in this simulation study.

Human D_2 RO predictions

The rat PBPKPD model structure (Fig. 1) was used to predict the D_2 RO *versus* time profile of antipsychotics in humans by substituting all parameters of the rat model by their human analogues, according to the following methods:

- (1) Human population PK parameters estimated using total plasma concentrations were obtained either from models developed in-house or from published literature (Table I).
- (2) Physiological parameters, such as blood flow to the brain and the brain volumes were obtained from literature (Table II).
- (3) Passive permeability transport across the BBB was scaled from *in vitro* or *in vivo* rat to *in vivo* human based on the assumption that permeability for passive diffusion per cm^2 of brain endothelial surface area is identical the between different systems.
- (4) Active efflux transport for PAL and RIS was scaled using pertinent information on Pgp protein expression in the different systems as a scaling factor.
- (5) Receptor binding was either derived from *in vitro* Ki values or *in vivo* Kd values corrected for differences between the *in vitro* and the *in vivo* system of the same species.
- (6) Experimentally determined values of the fraction unbound in human plasma and in rat brain were obtained from the literature. Unbound fraction in human brain is assumed to be equal to the unbound fraction in rat brain.

Different approaches were used to obtain human parameters and they were detailed as Approaches A-C in this section.

Approach A was based only on human *in vitro* information (*in vitro* apparent permeability, efflux ratio (ER), *in vitro* Ki and k_{off}).

Approach B was based on the *in vivo* parameters (rCL_{bev} , rCL_{eff} , Kd_{rat} , $k_{off-rat}$) obtained from the rat PBPKPD model.

Approach C was aimed at using minimal information to get the best predictions of human D_2 RO by integrating approaches A and B.

All the parameters values used for these simulations are presented in Table III.

Approach A: Human D_2 RO predictions based on *in vitro* information

Passive drug transport at the BBB

Experimentally determined *in vitro* apparent permeability (P_{app}) values were used to predict passive transport of antipsychotics across the BBB. Specifically, values of the v permeability across multidrug resistance Madin-Darby canine kidney (MDR1-MDCK) type II cell monolayers were obtained from Summerfield *et al.* (32). Permeability determined while attenuating transporters denotes the ability of the molecule to traverse membranes by passive means (41). These P_{app} values were translated to a meaningful parameter of human brain extra-vascular clearance (hCL_{bev}) across the BBB by taking the product of P_{app} and human brain endothelial surface area of $20 m^2$ (27).

Passive and active drug transport at the BBB

For the antipsychotics PAL and RIS that are known to have both active and passive transport across the BBB, the drug transport component was derived from P_{app} and *in vitro* efflux ratio (ER) determinations. ER is commonly used as an indicator of active drug transport in CNS drug discovery. ER is calculated as the ratio of effective permeability for a drug from the basal side to the apical side to that in the opposite direction (37). ER was used to calculate the human active efflux clearance (hCL_{eff}) of RIS and PAL. The parameters describing hCL_{bev} and hCL_{eff} accounting for active transport were derived based on Kwon *et al.* (42), underlying derivations are presented in Appendix 1.

$$hCL_{bev} \left(\frac{L}{h} \right) = \frac{2 * P_{app} * HBSA}{ER + 1} \quad (Eq1)$$

$$hCL_{eff} \left(\frac{L}{h} \right) = \frac{2 * P_{app} * HBSA * (ER - 1)}{ER + 1} \quad (Eq2)$$

Table I Human Population Pharmacokinetic Parameters (Inter-Individual Variability as % Coefficient of Variation) Used in the Human D₂RO Predictive Model

	Clozapine	Haloperidol	Olanzapine	Paliperidone	Quetiapine
V _c (L)	719 (62)	401 (37)	1150 (75)	395.4 (47)	380 (10)
CL (L/h)	37.9 (28)	53.0 (44)	19.5 (58)	14.15 (45)	96.0 (59)
V _p (L)	–	1500	–	–	–
Q (L/h)	–	140	–	–	–
F (%)	– ^a	60	– ^a	– ^a	– ^a
K _a (h ⁻¹)	1.37 (24)	0.230	0.600 (32)	2.49	2.50 (80)
DUR (h)	–	–	–	22.87	–

Clozapine, Olanzapine and Quetiapine: Reference (25); Haloperidol and Paliperidone: Parameters obtained from model developed in-house; Risperidone: Reference (26)

V_c-central volume of distribution, CL-clearance, V_p-peripheral volume of distribution, Q-inter-compartmental clearance, F-absolute bioavailability, K_a-absorption rate constant, DUR- duration of zero-order absorption

^a Not estimated and assumed to be 100%

hCL_{beV} and hCL_{eff} represent the passive permeability and active transport clearance across the BBB in humans, respectively. Papp represents the *in vitro* apparent permeability and HBSA represents human brain endothelial surface area of 20 m².

Receptor binding parameters

In vitro K_{i, human} values were used as the parameter K_d (equilibrium constant). If available, *in vitro* or *ex vivo* experimentally determined k_{off} values were used in these simulations (Table III). If experimental k_{off} values were not available, then calculated k_{off} values based on K_i and k_{off} correlation of different antipsychotics were used, as reported previously (5).

Approach B: Human D₂RO predictions based on *in vivo* information

The appropriateness of using the available rat hybrid PBPKPD model to determine *in vivo* parameters for human D₂RO predictions was assessed. Binding constants (K_{on} and K_{off}) and clearances (rCL_{beV} and rCL_{eff}) were obtained using PBPKPD models developed by us previously (7,8). This *in vivo* model based information was only available for OLZ, PAL and RIS.

Table II Physiological Values Used in the Human D₂RO Predictive Model

	Value	Reference
Human cerebral blood flow (L/h)	36.0	(27)
Human brain extravascular volume (L)	1.40	(28)
Human brain vascular volume (L)	0.150	(28)
Human striatal volume (L)	0.00700	(29)
Human cortex volume (L)	1.08	(28)
Dopamine D ₂ receptor density in human striatum (nM)	28.0	(30)
5-HT _{2A} receptor density in human frontal cortex (nM)	195	(31)

Passive drug transport to the brain

Calculated Papp (Papp_{calc}) values were derived as the ratio between PBPKPD model-estimated *in vivo* rCL_{beV} and rat brain endothelial surface area (150 cm²/g) and then normalized for an average rat brain weight of 2 g/250 g of rat (32). The product of Papp_{calc} and the human brain endothelial surface area (20 m²) was used as the hCL_{beV} - the passive transport clearance across the human BBB.

Active drug transport from the brain

Human active efflux clearance was predicted based on the PBPKPD model-estimated rCL_{eff} and mdr1a protein expression in micro vessels in mouse. Mdr1a expression values for rats were not available; hence, mdr1a expression in rat brain was assumed to be equal to that of mouse. Mouse mdr1a expression was documented as 14.1 fmol/μg of protein, and MDR1 expression in human brain was documented as 6.06 fmol/μg of protein (11). The following Eq. (Eq 3) describes the assumed relationship that was used to derive the hCL_{eff}.

$$hCL_{eff} \left(\frac{L}{h} \right) = rCL_{eff} \left(\frac{L}{h} \right) * \frac{MDR1 \text{ expression in human brain}}{Mdr1a \text{ expression in rat brain}} \quad (Eq3)$$

Receptor binding parameters

Model estimated *in vivo* k_{on-rat} and k_{off-rat} values were used as *in vivo* human k_{on} and k_{off} assuming that these drug-specific parameters do not require any scaling between species (9). For OLZ, model estimated *in vivo* K_{d-rat} and k_{off-rat} values were taken from our previous publication (7). For RIS and PAL, *in vivo* binding constants were obtained from the extended model structure where the time courses for D₂ and 5-HT_{2A} receptor binding were modeled together (8). These parameters are shown in Table IV.

Table III *In Vitro*, *In Vivo* and *Ex Vivo* Values Estimates Used in the Human D₂RO Predictive Model

	Clozapine	Haloperidol	Olanzapine	Paliperidone	Quetiapine	Risperidone
Fraction unbound in brain	0.011 ^a	0.023 ^b	0.034 ^a	0.0755 ^c	0.025 ^a	0.0699 ^c
Fraction unbound in plasma	0.0300 ^d	0.0800 ^e	0.0700 ^m	0.226 ^f	0.170 ^e	0.100 ^f
Approach A: Human D ₂ RO predictions based on <i>in vitro</i> information						
Papp × 10 ⁻⁶ (cm/s)	28.3 ^a	28.6 ^a	15.7 ^a	16.8 ^g	33.0 ^a	19.8 ^g
CL _{beV} (L/h) derived from Papp	2.04	2.06	1.13	7.80	2.36	12.96
Efflux Ratio	–	–	–	2.10 ^g	–	1.20 ^g
CL _{eff} (L/h) based on ER	–	–	–	8.58	–	2.59
<i>In vitro</i> Ki (nM)	82.0 ^h	0.700 ^h	5.10 ⁱ	2.075 ^e	155 ^h	2.175 ^e
k _{off} (h ⁻¹)	83.16 ^h	1.02 ^h	2.34 ^h	1.56 ^{j,n}	180.78 ^h	1.56 ^j
Approach B: Human D ₂ RO predictions based on <i>in vivo</i> information						
Papp _{calc} × 10 ⁻⁶ (cm/s)	–	–	100	493 ⁿ	–	493
CL _{beV} (L/h) based on Papp _{calc}	–	–	72.2	355 ⁿ	–	355
CL _{eff} (L/h) scaled from rat	–	–	NA	11594	–	2486
k _{off} (h ⁻¹)	–	–	3.04 ^k	0.671 ^{l,n}	–	0.671 ^l
Approach C: Human D ₂ RO predictions integrating <i>in vitro</i> and <i>in vivo</i> information						
Corrected <i>In vivo</i> Kd (nM)	–	–	4.38	0.352	–	0.395

^a Reference (32); ^b Reference (33); ^c Reference (34); ^d Reference (35); ^e In-house values; ^f Reference (36); ^g Reference (37); ^h Reference (38); ⁱ Reference (39); ^j Reference (5); ^k Reference (7); ^l Reference (8); ^m Reference (40)

NA Not applicable

ⁿ Assumed to be equal to risperidone

Approach C: Human D₂RO predictions integrating *in vitro* and *in vivo* information

Passive and active drug transport to the brain

Scaling and calculation used in Approach A were also applied in the integrated Approach C.

Table IV Brain PKPD Model Parameter Estimates (% Relative Standard Error) Obtained from rat PBPKPD Model and Used in the Human D₂RO Predictive Model (Approach B)

	Olanzapine ^a	Paliperidone ^b	Risperidone ^b
CL _{beV} (L/h/kg)	0.433 (16)	2.13 ^c	2.13 (29)
CL _{eff} (L/h/kg)	NA	46.5 (28)	9.97 (28)
Kd (nM) – D ₂ binding	14.6 (7)	0.463 ^c	0.463 (14)
k _{off} (h ⁻¹) – D ₂ binding	3.04 (24)	0.671 ^c	0.671 (19)
Kd (nM) – 5-HT _{2A} binding	NA	0.219 ^c	0.219 (15)
k _{off} (h ⁻¹) – 5-HT _{2A} binding	NA	0.525 ^c	0.525 (25)

^a Reference (7)

^b Reference (8)

^c Assumed to be equal to risperidone

NA Not applicable

Receptor binding parameters

In vivo Kd_{human} parameters were corrected for the differences between *in vitro* and *in vivo* scenarios by normalizing model estimated *in vivo* Kd_{rat} and *in vitro* Ki values for rat and human, as shown in Eq. (Eq 4).

$$Kd_{human}(nM) = In vitro Ki_{human} * \frac{In vivo Kd_{rat}}{In vitro Ki_{rat}} \quad (Eq4)$$

In vivo k_{off-human} values were assumed to be equal to *in vitro* or *ex vivo* experimentally determined k_{off} values.

Human 5-HT_{2A}RO predictions

The objective of this exercise was to check the utility of the extended model structure to predict human D₂RO and 5-HT_{2A}RO. *In vitro* Ki_{human} and Ki_{rat} for PAL were 0.250 nM (43). *In vitro* Ki_{human} and Ki_{rat} for RIS were 0.160 and 0.210 nM, respectively (43,44). We were unable to find k_{off} value for 5-HT_{2A} binding from any *in vitro* source and so, the *in vivo* based Approach B and the integrated Approach C were applied for these predictions.

Human D₂ receptor occupancy simulations

For each approach (A-C), 1000 human D₂RO- time course curves were simulated at clinically relevant doses, administered orally. Differential equations (Appendix 2) explaining the pharmacokinetics and pharmacodynamics of antipsychotics were used in these simulations as implemented in R (Version 3.1.0) using the deSolve package (45). Inter-individual variability (IIV) in the population pharmacokinetic parameters was accounted for in these simulations. The predictive power of this translational approach was determined by comparing these simulations with observed human D₂RO. In clinical trials, human D₂RO information were collected after repeated dosing and at steady state conditions. Hence, time course of D₂RO was simulated and results at steady state (achieved within 2 or 3 weeks of repeated drug dosing) were compared with the observed steady state RO.

Predictions of human RO were performed for CLZ (500 mg/day), HAL (2 mg/day), OLZ (10 mg/day), PAL (9 mg/day), QTP (750 mg/day) and RIS (4 mg/day) dose levels and compared graphically with observed D₂RO. Additionally, for OLZ, RIS and PAL box plots of prediction errors were made to compare the applicability of the different approaches and their predictive power. For this purpose, D₂RO or both D₂RO and 5-HT_{2A}RO predictions were made for a drug treatment of 3 weeks, at a single time point (12 h after the last dose of OLZ, RIS and 2 h after the last dose of PAL). These predictions were then compared with the median of the actual observations. The selection of dose and time points was based on the availability of data.

% Prediction Error (PE) was calculated as follows:

$$\%PE = 100 * \frac{\text{Median Predicted RO} - \text{Median Observed RO}}{\text{Median Observed RO}} \quad (\text{Eq5})$$

The median D₂RO observed experimentally for OLZ, PAL and RIS were 54.9, 77.4, 75.8%, respectively. The 5-HT_{2A}RO observed for RIS was 100% (46).

RESULTS

Human D₂RO predictions

Approach A

This approach predicted the time course of human D₂RO well for five of the antipsychotics, but not for HAL, as depicted in Fig. 2. The percentage prediction bias of these predictions is depicted for OLZ, PAL and RIS in Table V and Fig. 3.

Approach B

The predictive model based on *in vivo* model estimated parameters under-predicted the human D₂RO for OLZ, RIS and PAL (Table V, Fig. 3).

Approach C

The predictive model using the “corrected” *in vivo* K_d_{human} estimates predicted human D₂RO for OLZ are at the best when compared to the other approaches (Fig. 3). For PAL and RIS, the D₂RO was slightly over-predicted and the prediction bias was large in comparison to Approach A (Figs. 3 and 4) and Table V.

Human 5-HT_{2A}RO predictions

The extended predictive model using the “corrected” *in vivo* K_d_{human} estimates predicted the human 5-HT_{2A}RO for risperidone better than approach B. Human D₂RO predictions were similar to that of the model which only accounts for the D₂ receptor binding, although the prediction bias for Approach B is lower (Table V, Fig. 5).

DISCUSSION


This study aimed to utilize the recently proposed rat PBPKPD model structure (7,8) in a translational framework to scale pharmacokinetic and pharmacodynamic information from rats to human. The objective of this work was also to determine the minimal information required to be included in this translational framework to predict the D₂RO during the early drug discovery phase, while taking into account distribution to the brain and receptor binding.

In this simulation study, three approaches (A, B and C) were used to predict D₂RO in human. Approach A uses information based on *in vitro* studies, Approach B uses information obtained from *in vivo* studies based on rats and Approach C integrates both *in vitro* and *in vivo* based information. Due to limitation of *in vivo* based information, Approach B and Approach C were applied only for olanzapine, risperidone and paliperidone. The following part discusses the implementation of these approaches to translate permeation of drugs to brain and their binding to D₂ receptors.

Translation of passive drug transport at the BBB

It is well known that tight junctions and active efflux transporters present at the luminal surface of the BBB are involved in the distribution of any substance to the brain. Hence, hCL_{bev} and hCL_{eff} were included in this model structure to

Fig. 2 Observed and predicted steady-state D_2 receptor occupancy in humans after oral administration of antipsychotics at clinically relevant doses. Simulations were performed using the rat PBPKPD model structure integrated with *in vitro* apparent permeability, efflux ratio and *in vitro* binding information (Approach A). Depicted are the observed D_2 RO (dots) and the shaded area represent the 95% prediction limits of the simulated D_2 RO. The medians of the simulated D_2 RO are represented as a solid line.



explain passive permeability across the BBB and active efflux processes in a mechanistic manner.

In vitro effective permeability of compounds with various characteristics across human primary brain endothelial cells was comparable to those obtained with bovine and rat capillary endothelial cells (10). So, a simplistic way of translation of

passive permeability across the BBB between species is by accounting for the differences in system-specific brain endothelial surface area and utilize the *in vitro* effective permeability information without any scaling between species. In Approach A, passive permeability of the compounds across the BBB was calculated as the product of human brain endothelial surface area and P_{app} values obtained from *in vitro* MDR1-MDCK.

Approach B used the passive permeability of compounds across the BBB under *in vivo* conditions. This was achieved by estimating model parameter explaining the passive transport of drugs across the BBB by fitting a PBPKPD model to plasma and whole brain concentration data obtained from rats. $P_{app,calc}$ (permeability across the BBB *in vivo*) values were derived from PBPKPD model-estimated *in vivo* rCL_{bev} and rat brain endothelial surface area.

The hCL_{bev} values calculated based on *in vitro* P_{app} or $P_{app,calc}$ (calculated based on rCL_{bev}) values were different (Table III) and this could direct towards a theory on different efficiency of drug transport in *in vitro* and *in vivo* systems. However, it should be noted that the PBPKPD model-based estimate rCL_{bev} (and thereby $P_{app,calc}$) was based on whole brain concentration and therefore this data do not differentiate the

Table V Prediction Bias (in %) Across Different Approaches Used for Predicting Human D_2 RO

	Olanzapine	Paliperidone	Risperidone
Approach A	-10	-3	1
Approach B	-53	-40	-33
Approach C	-4	22	26
Human D_2 RO using extended model structure			
Approach B	NA	NA	-19
Approach C	NA	NA	25
Human 5-HT _{2A} RO using extended model structure			
Approach B	NA	NA	-22
Approach C	NA	NA	-3

NA Not applicable




Fig. 3 Box plots representing the % prediction error (PE) for different approaches where *in vitro*, *in vivo* and integrated *in vitro* and *in vivo* information were used to predict the human D₂RO. Letters **A**, **B** and **C** denotes the three different approaches, Approach A, Approach B and Approach C, respectively.

influence of the cerebrospinal fluid barrier and other micro-environment conditions on the transport of drug at the BBB.

Fig. 4 Observed and predicted steady-state D₂ receptor occupancy (D₂RO) in humans after oral administration of risperidone or paliperidone at clinically relevant doses. Depicted are the observed D₂RO (dots) and the shaded area represent the 95% prediction limits of the simulated D₂RO. The medians of the simulated D₂RO are represented as a solid line. Panel (a) and Panel (b) represent the human D₂RO predictions for paliperidone achieved by approaches A and C, respectively. Panel (c) and Panel (d) represent the human D₂RO predictions for risperidone based on approaches A and C, respectively.





Fig. 5 Box plots represent the % prediction error (PE) for human D₂RO and 5-HT_{2A}RO predictions of risperidone at 4 mg/day dose. % PE for human D₂RO predictions obtained by both D₂ model structure (D₂MS) and an extended model structure including 5-HT_{2A}RO (5-HT_{2A}MS) are compared in the left hand panel. Right hand panel represents the human 5-HT_{2A}RO predictions of risperidone obtained from the extended model structure using approach B and C.

In addition, Papp_{calc} was derived using reported rat brain endothelial surface area, which ranges from 100 to 240 cm² per g brain tissue (47,48). These underlying assumptions and lack of information limited the application of Approach B.

Notwithstanding this limitation, deriving a relationship between model-estimated rCL_{beV} (and thereby $Papp_{\text{calc}}$) and *in vitro* Papp based on more compounds might help to improve the translation approach. However, the limited number of compounds used in our PKPD analysis did not allow us to elicit such a relationship. So, in the absence of such a relationship, it seems to be more appropriate to base the scaling of *in vitro* Papp values to hCL_{beV} on human brain endothelial surface area only. Hence, while integrating *in vitro* and *in vivo* information (i.e., Approach C), the calculated hCL_{beV} was based only on *in vitro* Papp value and human brain endothelial surface area.

Translation of active drug transport at the BBB

Predicting active efflux clearance at the human BBB using *in vitro* information was challenging and complicated. In this simulation study, *in vitro* ER was used to account for the active drug transport out of the brain. In Approach A, *in vitro* ER was used to calculate the drug transport across the BBB by means of active transport. Derivation based on Kwon *et al.* (42) explains the transport of compound across membranes under *in vitro* conditions using Papp and ER and by using this derivation and HBSA, the parameters hCL_{beV} and hCL_{eff} were calculated for human conditions. This translation approach is simple and based only on information from *in vitro*. Hence, this will be a useful tool to predict brain transport in human brain environment at early stages of drug development. Nevertheless, it should be noted that this translation approach accounts only for differences in brain endothelial surface area between species and excludes differences in transporter expression levels. Extension of this approach accounting for those differences on microenvironment levels between different species would help to improve predictions of drug transport at BBB.

Subsequently, active efflux transport was also scaled to the human conditions based on the estimates obtained from the rat PBPKPD model parameters and expression of *mdr1a* protein in both species (i.e., Approach B). As described earlier, this PBPKPD model-based estimate of rCL_{beV} (and thereby $Papp_{\text{calc}}$) and rCL_{eff} were based on whole brain concentration and therefore had no ability to differentiate microenvironment conditions at the BBB. In addition, due to non-availability of the appropriate *mdr1a* expression data in rats, it was assumed that it is equal to that of mouse. Additionally, the active transport was included as a linear process rather than non-linear as usually described for *in vitro* systems, since the free concentrations of drug at the BBB (in rats) were much lower than the concentrations used *in vitro*, and remain most likely below the K_m (concentration required for the half-maximal transport) for the transporter, which makes this assumption acceptable. A proper evaluation of these assumptions would help to substantiate the claims, however due to

lack of human brain drug exposure information these assumptions are seldom evaluated. Nevertheless, this work provides a framework to account for the active drug transport in humans. It is noteworthy that both these approaches (Approach A and B) are plausible because of their mechanistic basis.

Translation of receptor binding properties

Danhof *et al.* (49) proposed that the values of drug-specific parameters such as target affinity are likely to be identical between species and individuals. This would imply that the binding rate constants estimated in rats could be used to extrapolate the pharmacodynamics from rat to human. Hence, it is appropriate to include *in vitro* or *in vivo* binding constants in this model structure to predict human D_2RO . This predictive model structure was obtained from a preclinical system where the drug binding to D_2 receptors was explained by accounting for the association and dissociation rates of antipsychotics. The model estimated *in vivo* Kd_{rat} values for OLZ were close to *in vitro* Ki_{rat} values (rat cloned D_{2L} system – 17 nM), but *in vitro* Ki_{human} values (human cloned D_{2L} system- 5.1 nM) were different from both these values of the rat system. Additionally, PAL and RIS *in vitro* Ki_{rat} values (most commonly reported as 2 nM) are different from the model estimated *in vivo* Kd_{rat} values (0.364 nM). The human D_2RO predictions for OLZ, RIS and PAL were not consistent with the observed human D_2RO data when model estimated *in vivo* Kd_{rat} was used as the *in vivo* Kd_{human} parameter in the predictive model. This challenges the general belief that drug-specific parameters like Kd can be used across species without any scaling. However, this difference between the *in vivo* and *in vitro* scenario for the same species could arise from the assumptions used in both *in vitro* calculations and model estimations. Additionally, radioligand selection and disturbances in assumed equilibrium conditions in *in vitro* and *in vivo* systems could lead to biased or inappropriate Ki calculations (50).

Extension of predictive model

It has been demonstrated that the binding to both D_2 and 5-HT_{2A} receptors (extended model) was essential to explain the relationship between drug exposure and receptor occupancy in the preclinical system with good precision (8). The model estimates of *in vivo* Kd_{rat} for RIS are influenced by the brain distribution kinetics and it was elucidated that the brain-to-plasma ratio (in rats) is not constant for RIS, suggesting an influence of specific binding to receptors on the brain-kinetics (8). Hence, an extended model structure was used to predict both D_2 and 5-HT_{2A} receptor occupancy in humans. The extended structure predicted 5-HT_{2A}RO well. Surprisingly, the D_2RO predictions achieved by using these two different model structures (D_2 alone versus $D_2 + 5-HT_{2A}$) remained close to each other; and this extension, which was

essential for model fitting in a preclinical system, did not significantly improve the human D₂RO predictions (at least for Approach C). Nevertheless, this extended model structure underscores the ability of this model framework to be flexible and extendable to other receptor types.

Our objective was also to study the minimal information required to predict human D₂RO. In general, human D₂RO was predicted well for all compounds except haloperidol when only *in vitro* information (Approach A) was used in the simulations. This demonstrates the ability of this model structure to predict human D₂RO with minimal *in vitro* information.

In this simulation study, the time course of plasma concentrations was obtained from available population pharmacokinetic parameters. It is also possible to predict these pharmacokinetic parameters based on *in silico* and *in vitro* information using commercially available tools, like Simcyp (Simcyp Ltd., Sheffield, UK). So, the requirement of population pharmacokinetic parameters obtained from clinical studies is not essential.

For HAL, D₂RO predictions were lower than the observations. This may be related to the high ratio of unbound concentrations of HAL in brain and plasma, which is close to 4 in rats (51). This high brain to plasma ratio may indicate a unique active influx transport to the brain. In addition, it has been documented that the metabolism of HAL involves a conversion of HAL to reduced haloperidol, and back-conversion of reduced haloperidol to HAL (52) in the brain of guinea pigs. Accounting for this metabolism and/or active influx transport may help to improve predictions. Extending this predictive model structure to include such complexity is practically possible, if sufficient information about each related process is available beforehand.

Applications of this predictive tool are not limited to only predicting D₂RO in early drug discovery but also in selecting appropriate first in human doses based on pharmacodynamics. It is not anticipated that predictive tools will completely replace the need for experiments, though it is plausible that this tool can help to design more informative and more efficient clinical studies.

CONCLUSION

A general translational framework was developed which is based on a mechanism-based approach and accounts for the different processes involved in the transport of drug to the brain. Based on, *in vitro* information (Papp, ER and Ki), the model was able to predict the human D₂RO for drugs distributed to the brain by passive permeability and active transport processes. This model structure with an appropriate extension also predicted the human 5-HT_{2A}RO well.

ACKNOWLEDGMENTS AND DISCLOSURES

Martin Johnson is an employee of Astrazeneca, Cambridge, UK. Venkatesh Pilla reddy is an employee of Astrazeneca, Cambridge, UK and holder of AstraZeneca shares. This research article was prepared within the framework of project no. D2-104 of the Dutch Top Institute Pharma (Leiden, the Netherlands; www.tipharma.com). The authors have no conflicts of interest that are directly relevant to the contents of this research article.

APPENDIX I

Derivation of the relationship between CL_{beu}, CL_{eff}, Papp, SA and ER

1. Relationship between CL_{beu}, CL_{eff}, PS and PS_{pgp}

The derivation is based on the model described by Kwon *et al.* (42). The model describes the passive and active transport from the apical side (A) to the basal side (B) of enterocytes. A similar model was described by Kalvass *et al.* (53) for various situations where efflux transporters such as P-glycoprotein (Pgp) are involved, including the blood–brain barrier.

Equation (Eq 2) of Kwon *et al.* (42) describes the net change of the amount in the cells (M), i.e., the rate of accumulation in the cell.

$$\frac{dM}{dt} = PS1 * C_A - PS2 * C_{ent} - PS_{pgp} * C_{ent} + PS4 * C_B - PS3 * C_{ent} \quad (A1)$$

where C_A and C_B are the extracellular concentration at the apical and basal side, respectively, C_{ent} is the intracellular concentration, PS1, PS2, PS3 and PS4 are the products of membrane permeability and surface area for passive transport from A to intracellular, from intracellular to A, from intracellular to B and from B to intracellular, respectively, and PS_{pgp} is the product PS for active transport from intracellular to A by the transporter Pgp.

In situations where the concentrations at both sides A and B are constant, C_{ent} will be constant, and the net change of M will be zero. For dM/dt = 0, Eq. (Eq 5) can be rearranged and simplified to:

$$C_{ent} = \frac{C_A + C_B}{2 + \frac{PS_{pgp}}{PS}} \quad (A2)$$

The net transport over the basal membrane in the direction from apical to basal side is

$$Net\ basal\ membrane\ flux_{AB} = PS * C_{ent} - PS * C_B \quad (A3)$$

Replacing C_{ent} by Eq. (A1)

$$Net\ basal\ membrane\ flux_{AB} = \frac{PS * C_A - (PS + PS_{pgp}) * C_B}{2 + \frac{PS_{pgp}}{PS}} \quad (A4)$$

The net transport over the apical membrane in the direction from apical to basal side is

$$Net\ apical\ membrane\ flux_{AB} = PS * C_A - (PS + PS_B) * C_{ent} \quad (A5)$$

Replacing C_{ent} by Eq. (A1) yields the same result as Eq. (A3), since it was assumed that there is no accumulation in the cells.

The passive diffusion clearance CL_{bev} is defined as the passive membrane flux from A to B divided by the concentration C_A , so it follows from Eq. (A3):

$$CL_{bev} = \frac{PS}{2 + \frac{PS_{pgp}}{PS}} \quad (A6)$$

The active efflux clearance CL_{eff} is defined as the efflux by P_{gp} of C_B , so from Eq. (A3):

$$CL_{eff} = \frac{PS}{2 + \frac{PS_{pgp}}{PS}} \quad (A7)$$

Equations (A5) and (A6) define the relationship between the model parameters CL_{bev} and CL_{eff} and their determinants, PS and PS_{pgp} .

Note that the passive CL_{bev} is dependent on PS_{pgp} . This is due to the fact that the active efflux lowers the intracellular concentration C_{ent} , reducing the effective concentration gradient over the basal membrane. As a result, the passive transport is lower compared to the situation in the absence of active efflux.

2. Efflux Ratio

The Efflux Ratio is defined as the ratio of the transport clearance (CL_{BA}) from B to A if $C_A = 0$ and the transport clearance (CL_{AB}) from A to B if $C_B = 0$ (37). From Eqs. (A3), (A5) and (A6) the following equations can be derived:

$$Efflux\ Ratio\ (ER) = \frac{PS + PS_{pgp}}{PS} \quad (A8)$$

$$Efflux\ Ratio\ (ER) = \frac{CL_{bev} + CL_{eff}}{CL_{bev}} \quad (A9)$$

$$PS_{pgp} = PS * (ER - 1) \quad (A10)$$

$$CL_{eff} = CL_{bev} * (ER - 1) \quad (A11)$$

From Eqs. (A3) and (A7) it can be derived that the ratio C_A/C_B (plasma/brain ratio) at steady state is equal to the efflux ratio ER.

3. Relationship between P_{app} and PS

The apparent permeability P_{app} is determined by measuring the net flux over the cell layer in the absence of active efflux ($PS_{pgp} = 0$). In this case Eq. (A3) can be simplified to:

$$Net\ basal\ membrane\ flux_{AB} = \frac{PS * (C_A - C_B)}{2} \quad (A12)$$

P_{app} is obtained by dividing by the concentration gradient, after normalizing for surface area (SA):

$$P_{app} = \frac{PS}{2 * SA} \quad (A13)$$

Or

$$PS = 2 * P_{app} * SA \quad (A14)$$

The factor 2 reflects the passage over two membranes in series.

4. Relationship between CL_{bev} , CL_{eff} , P_{app} and ER

Combining Eqs. (A5), (A6), (A9), (A10) and (A13) yields the following equations:

$$CL_{bev} = \frac{2 * P_{app} * SA}{ER + 1} \quad (A15)$$

$$CL_{eff} = \frac{2 * P_{app} * SA * (ER - 1)}{ER + 1} \quad (A16)$$

Equations (A14) and (A15) can be used to calculate the model parameters CL_{bev} and CL_{eff} from the experimentally obtained values P_{app} and ER.

APPENDIX 2

PBPKPD model used to predict human D_2RO is defined by the following differential equations:

$$\begin{aligned}
d(A_{bv})/dt &= (CL_{bv}/V_{plasma}) * A_{plasma} - (CL_{bv}/V_{bv}) * A_{bv} - (CL_{bev}/V_{bv}) * f u_{plasma} * A_{bv} + (CL_{bev}/V_{bv}) * f u_{brain} * A_{bev} \\
&+ (CL_{bev}/V_{bv}) * f u_{brain} * A_{bev} \quad d(A_{bev})/dt \\
&= (CL_{bev}/V_{bv}) * f u_{plasma} * A_{bv} - (CL_{bev}/V_{bev}) * f u_{brain} * A_{bev} - (CL_{eff}/V_{bv}) * f u_{brain} * A_{bev} - (CL_{st}/V_{bev}) * f u_{brain} * A_{bev} + \\
&(CL_{st}/V_{stf}) * f u_{brain} * A_{stf} \quad d(A_{stf})/dt \\
&= (CL_{st}/V_{bev}) * f u_{brain} * A_{bev} - (CL_{st}/V_{stf}) * f u_{brain} * A_{stf} - k_{on} * f u_{brain} * A_{stf} * (B_{max} - CB) + k_{off} * A_{stb} \quad d(A_{stb})/dt \\
&= k_{on} * f u_{brain} * A_{stf} * (B_{max} - CB) - k_{off} * A_{stb}
\end{aligned}$$

Where,

subscripts plasma, bv, bev, stf, sb represent volume (V) and amount (A) of drug in plasma, brain-vascular, brain-extravascular, striatum-free and striatum-bound compartments, respectively;

CL_{bv} , CL_{bev} , CL_{st} represent transport clearance of drug to brain-vascular, brain-extravascular, striatum-free compartments, respectively;

CL_{eff} represents the active efflux transport clearance of drug from brain-extravascular compartment;

B_{max} is the dopamine D₂ receptor density in nM;

CB is the concentration bound to receptor as $(A_{stb}/V_{stb})/(MW/1000)$ in nM;

MW is the molecular weight of the drug;

D₂RO is calculated as $CB/B_{max} * 100\%$.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

- de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D(2) occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. *AAPS J*. 2011;13(1):121–30.
- Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1-dopamine and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side-effects. *Arch Gen Psychiatry*. 1992;49(7):538–44.
- Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, *et al*. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind pet study of schizophrenic-patients. *Biol Psychiatry*. 1993;33(4):227–35.
- Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, *et al*. High levels of dopamine D-2 receptor occupancy with low-dose haloperidol treatment: a PET study. *Am J Psychiatr*. 1996;153(7):948–50.
- Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, *et al*. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. *CNS Drugs*. 2006;20(5):389–409.
- Grimwood S, Hartig PR. Target site occupancy: emerging generalizations from clinical and preclinical studies. *Pharmacol Ther*. 2009;122(3):281–301.
- Johnson M, Kozielska M, Reddy VP, Vermeulen A, Li C, Grimwood S, *et al*. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D(2) receptor occupancy of olanzapine in rats. *Pharm Res*. 2011;28(10):2490–504.
- Kozielska M, Johnson M, Reddy VP, Vermeulen A, Li C, Grimwood S, *et al*. Pharmacokinetic-pharmacodynamic modeling of the D2 and 5-HT2A receptor occupancy of risperidone and paliperidone in rats. *Pharm Res*. 2012;29(7):1932–48.
- Danhof M, De Lange ECM, la Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. *Trends Pharmacol Sci*. 2008;29(4):186–91.
- Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, *et al*. In vitro models for the blood-brain barrier. *Toxicol in Vitro*. 2005;19(3):299–334.
- Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, *et al*. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. *J Neurochem*. 2011;117(2):333–45.
- Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. *Clin Pharmacol Ther*. 2008;83(6):909–12.
- Attarbaschi T, Geiss-Granadia T, Sacher J, Klein N, Mossaheb N, Wiesegger G, *et al*. Striatal D2 receptor occupancy in bipolar patients treated with olanzapine. *Biol Psychiatry*. 2005;57(8):169S.
- Dresel S, Mager T, Rossmuller B, Meisenzahl E, Hahn K, Moller HJ, *et al*. In vivo effects of olanzapine on striatal dopamine D-2/D-3

- receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. *Eur J Nucl Med.* 1999;26(8):862–8.
15. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D-2 receptor occupancy in relation to clozapine serum concentration - a pet study in schizophrenic-patients. *Psychopharmacology (Berlin)*. 1995;118(2):B8.
 16. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by pet after single oral doses of haloperidol. *Psychopharmacology (Berlin)*. 1992;106(4):433–8.
 17. Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BPR, van Royen EA. Dopamine D-2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. *Psychiatry Res-Neuroimaging*. 1999;92(1):33–44.
 18. Nordstrom AL, Nyberg S, Olsson H, Farde L, Seeman P. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. *Arch Gen Psychiatry*. 1998;55(3):283–4.
 19. Nyberg S, Farde L, Halldin C. A PET study of 5-HT₂ and D-2 dopamine receptor occupancy induced by olanzapine in healthy subjects. *Neuropsychopharmacology*. 1997;16(1):1–7.
 20. Pilowsky LS, O'Connell P, Davies N, Busatto GF, Costa DC, Murray RM, et al. In vivo effects on striatal dopamine D-2 receptor binding by the novel atypical antipsychotic drug sertindole - A I-123 IBZM single photon emission tomography (SPET) study. *Psychopharmacology (Berlin)*. 1997;130(2):152–8.
 21. Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, et al. In vivo I-123 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. *Psychopharmacology (Berlin)*. 1999;141(2):175–81.
 22. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'h C, Maziere B, et al. Extrastriatal and striatal D-2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. *Br J Psychiatry*. 2001;179:503–8.
 23. Hagberg G, Gefvert O, Bergstrom M, Wieselgren IM, Lindstrom L, Wiesel FA, et al. N-[C-11] methylspiperone PET, in contrast to [C-11] raclopride, fails to detect D-2 receptor occupancy by an atypical neuroleptic. 1998;82 Suppl 3:147–60.
 24. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. 2008;197 Suppl 2:229–35.
 25. Catafau AM, Penengo MM, Nucci G, Bullich S, Corripio I, Parellada E, et al. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. *J Psychopharmacol*. 2008;22(8):882–94.
 26. Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. *J Pharmacokinetic Pharmacodyn*. 2007;34(2):183–206.
 27. Fagerholm U. The highly permeable blood–brain barrier: an evaluation of current opinions about brain uptake capacity. *Drug Discov Today*. 2007;12(23–24):1076–82.
 28. Rengachary SS, Ellenbogen RG. Principles of neurosurgery. Edinburgh: Elsevier Mosby; 2005.
 29. Yin DL, Valles FE, Fiandaca MS, Forsayeth J, Larson P, Starr P, et al. Striatal volume differences between non-human and human primates. *J Neurosci Methods*. 2009;176(2):200–5.
 30. Farde L, Hall H, Pauli S, Halldin C. Variability in D-2-dopamine receptor density and affinity - a pet study with [C-11] raclopride in man. *Synapse*. 1995;20(3):200–8.
 31. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. 4. Autoradiographic mapping of serotonin-2 receptors. *Neuroscience*. 1987;21(1):123–39.
 32. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo JJ, Coggon S, et al. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. *J Pharmacol Exp Ther*. 2007;322(1):205–13.
 33. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, et al. Toward an improved prediction of human in vivo brain penetration. *Xenobiotica*. 2008;38(12):1518–35.
 34. Liu XR, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, et al. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. *Drug Metab Dispos*. 2009;37(4):787–93.
 35. Keck PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. *J Clin Psychiatry*. 2002;63:3–11.
 36. Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma-protein binding of risperidone and its distribution in blood. 1994;114 Suppl 4:566–72.
 37. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. *Drug Metab Dispos*. 2008;36(2):268–75.
 38. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. *J Psychiatry Neurosci*. 2000;25(2):161–6.
 39. Seeman P. Atypical antipsychotics: mechanism of action. *Can J Psychiatry*. 2002;47(1):27–38.
 40. Kassahun K, Mattiuz E, Nyhart Jr E, Obermeyer B, Gillespie T, Murphy A, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. *Drug Metab Dispos*. 1997;25:81–93.
 41. Sun HD, Pang KS. Permeability, transport, and metabolism of solutes in caco-2 cell monolayers: a theoretical study. *Drug Metab Dispos*. 2008;36(1):102–23.
 42. Kwon H, Lionberger RA, Yu LX. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. *Mol Pharm*. 2004;1(6):455–65.
 43. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van GP, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. *Psychopharmacology (Berlin)*. 1996;124(1–2):57–73.
 44. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. *Mol Psychiatry*. 1998;3(2):123–34.
 45. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009.
 46. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT₂ and D(2) receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. *Am J Psychiatr*. 1999;156(2):286–93.
 47. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. *Pharm Res*. 2008;25(8):1737–50.
 48. Avdeef A. How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood–brain barrier permeability? *Eur J Pharm Sci*. 2011;43(3):109–24.
 49. Danhof M, de Jongh J, De Lange ECM, la Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. *Annu Rev Pharmacol Toxicol*. 2007;47:357–400.
 50. Hulme EC, Trevethick MA. Ligand binding assays at equilibrium: validation and interpretation. *Br J Pharmacol*. 2010;161(6):1219–37.
 51. Zhang G, Terry AV, Bartlett MG. Sensitive liquid chromatography/tandem mass spectrometry method for the

- simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2007;858(1–2):276–81.
52. Chang WH, Lin SK, Jann MW. Interconversions between haloperidol and reduced haloperidol in schizophrenic-patients and Guinea-pigs - a steady-state study. *J Clin Psychopharmacol.* 1991;11(2):99–105.
53. Kalvass JC, Pollack GM. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. *Pharm Res.* 2007;24(2):265–76.